NLPHL
MCID: NDL021
MIFTS: 41

Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL)

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Nodular Lymphocyte Predominant Hodgkin Lymphoma

MalaCards integrated aliases for Nodular Lymphocyte Predominant Hodgkin Lymphoma:

Name: Nodular Lymphocyte Predominant Hodgkin Lymphoma 58 70 32
Nlphl 58

Characteristics:

Orphanet epidemiological data:

58
nodular lymphocyte predominant hodgkin lymphoma
Prevalence: 1-9/1000000 (Worldwide),<1/1000000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:

Orphanet: 58  
Rare haematological diseases


Summaries for Nodular Lymphocyte Predominant Hodgkin Lymphoma

MalaCards based summary : Nodular Lymphocyte Predominant Hodgkin Lymphoma, also known as nlphl, is related to lymphoma, hodgkin, classic and b-cell lymphoma. An important gene associated with Nodular Lymphocyte Predominant Hodgkin Lymphoma is BCL6 (BCL6 Transcription Repressor), and among its related pathways/superpathways are FoxO signaling pathway and DNA Damage Response (only ATM dependent). The drugs Prednisone and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, t cells and bone, and related phenotypes are immunodeficiency and lymphadenopathy

Wikipedia : 73 Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is an indolent CD20(+) form of... more...

Related Diseases for Nodular Lymphocyte Predominant Hodgkin Lymphoma

Diseases related to Nodular Lymphocyte Predominant Hodgkin Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 73)
# Related Disease Score Top Affiliating Genes
1 lymphoma, hodgkin, classic 32.4 CFLAR BCL6
2 b-cell lymphoma 31.1 CFLAR CCND1 BCL6
3 lymphoma 31.0 PDCD1 CFLAR CCND1 BCL6
4 diffuse large b-cell lymphoma 30.9 PDCD1 CCND1 BCL6
5 lymphoma, non-hodgkin, familial 30.7 CFLAR CCND1 BCL6
6 follicular lymphoma 30.3 CCND1 BCL6
7 marginal zone b-cell lymphoma 30.2 CCND1 BCL6
8 peripheral t-cell lymphoma 30.0 PDCD1 CCND1 BCL6
9 leukemia, chronic lymphocytic 30.0 CFLAR CCND1 BCL6
10 cll/sll 29.8 PDCD1 CCND1 BCL6
11 t-cell/histiocyte rich large b cell lymphoma 11.6
12 rapidly involuting congenital hemangioma 10.8
13 progressive transformation of germinal centers 10.6
14 b-cell non-hodgkin lymphoma 10.5
15 composite lymphoma 10.4
16 47,xyy 10.4
17 anaplastic large cell lymphoma 10.3
18 gray zone lymphoma 10.3
19 hodgkin's lymphoma, lymphocytic-histiocytic predominance 10.3
20 exophthalmos 10.3
21 warthin tumor 10.3
22 aggressive b-cell non-hodgkin lymphoma 10.3
23 kaposi sarcoma 10.2
24 li-fraumeni syndrome 10.2
25 anemia, autoimmune hemolytic 10.2
26 ataxia and polyneuropathy, adult-onset 10.2
27 leukemia, acute myeloid 10.2
28 hermansky-pudlak syndrome 2 10.2
29 li-fraumeni syndrome 2 10.2
30 leukemia, acute lymphoblastic 10.2
31 deficiency anemia 10.2
32 exanthem 10.2
33 mantle cell lymphoma 10.2
34 sialadenitis 10.2
35 sarcoma 10.2
36 cauda equina syndrome 10.2
37 leukemia 10.2
38 leiomyoma 10.2
39 cholestasis 10.2
40 embryonal rhabdomyosarcoma 10.2
41 rhabdomyosarcoma 10.2
42 liver disease 10.2
43 spindle cell sarcoma 10.2
44 polyradiculopathy 10.2
45 adult lymphoma 10.2
46 hemolytic anemia 10.2
47 hodgkin's lymphoma, mixed cellularity 10.2
48 myeloid leukemia 10.2
49 hodgkin's lymphoma, nodular sclerosis 10.2
50 pathologic nystagmus 10.2

Graphical network of the top 20 diseases related to Nodular Lymphocyte Predominant Hodgkin Lymphoma:



Diseases related to Nodular Lymphocyte Predominant Hodgkin Lymphoma

Symptoms & Phenotypes for Nodular Lymphocyte Predominant Hodgkin Lymphoma

Human phenotypes related to Nodular Lymphocyte Predominant Hodgkin Lymphoma:

58 31 (show all 14)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 immunodeficiency 58 31 hallmark (90%) Very frequent (99-80%) HP:0002721
2 lymphadenopathy 58 31 hallmark (90%) Very frequent (99-80%) HP:0002716
3 fever 58 31 frequent (33%) Frequent (79-30%) HP:0001945
4 hyperhidrosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0000975
5 splenomegaly 58 31 occasional (7.5%) Occasional (29-5%) HP:0001744
6 hepatomegaly 58 31 occasional (7.5%) Occasional (29-5%) HP:0002240
7 fatigue 58 31 occasional (7.5%) Occasional (29-5%) HP:0012378
8 anorexia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002039
9 weight loss 58 31 occasional (7.5%) Occasional (29-5%) HP:0001824
10 breast carcinoma 58 31 occasional (7.5%) Occasional (29-5%) HP:0003002
11 abnormality of bone marrow cell morphology 58 31 occasional (7.5%) Occasional (29-5%) HP:0005561
12 pruritus 58 31 occasional (7.5%) Occasional (29-5%) HP:0000989
13 b-cell lymphoma 58 31 occasional (7.5%) Occasional (29-5%) HP:0012191
14 lymphoma 58 Very frequent (99-80%)

GenomeRNAi Phenotypes related to Nodular Lymphocyte Predominant Hodgkin Lymphoma according to GeneCards Suite gene sharing:

26 (show all 12)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-134 9.7 CCND1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.7 CCND1
3 Increased shRNA abundance (Z-score > 2) GR00366-A-21 9.7 CCND1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-210 9.7 CCND1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-211 9.7 CCND1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.7 PDCD1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-36 9.7 CCND1 PDCD1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.7 PDCD1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-59 9.7 PDCD1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.7 PDCD1
11 Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) GR00104-A-0 9.16 CCND1 PDCD1
12 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-2 8.8 CARD16 CCND1 PDCD1

Drugs & Therapeutics for Nodular Lymphocyte Predominant Hodgkin Lymphoma

Drugs for Nodular Lymphocyte Predominant Hodgkin Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 41)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
2
Cyclophosphamide Approved, Investigational Phase 4 50-18-0, 6055-19-2 2907
3
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
4
Vinblastine Approved Phase 4 865-21-4 13342 241903
5
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
6
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
7
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
8
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
9
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
10 Tubulin Modulators Phase 4
11 Antirheumatic Agents Phase 4
12 Immunosuppressive Agents Phase 4
13 Hormones Phase 4
14 Antimitotic Agents Phase 4
15 Alkylating Agents Phase 4
16 Immunologic Factors Phase 4
17 glucocorticoids Phase 4
18 Antineoplastic Agents, Hormonal Phase 4
19 Hormone Antagonists Phase 4
20 Anti-Inflammatory Agents Phase 4
21 Methylprednisolone Acetate Phase 4
22
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
23
Vinorelbine Approved, Investigational Phase 3 71486-22-1 60780 44424639
24
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
25
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
26
Ifosfamide Approved Phase 3 3778-73-2 3690
27
Etoposide Approved Phase 3 33419-42-0 36462
28
Lenograstim Approved, Investigational Phase 3 135968-09-1
29
Liposomal doxorubicin Phase 3 31703
30
Isophosphamide mustard Phase 3 100427
31 Etoposide phosphate Phase 3
32 Antibiotics, Antitubercular Phase 3
33 Anti-Bacterial Agents Phase 3
34
ofatumumab Approved Phase 2 679818-59-8 6918251
35
rituximab Approved Phase 1, Phase 2 174722-31-7 10201696
36
Fenretinide Investigational Phase 1, Phase 2 65646-68-6
37 Antineoplastic Agents, Immunological Phase 1, Phase 2
38 Immunoglobulins Phase 1, Phase 2
39 Protective Agents Phase 1, Phase 2
40 Antibodies, Monoclonal Phase 1, Phase 2
41 Antibodies Phase 1, Phase 2

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 First International Inter-Group Study for Nodular Lymphocyte-Predominant Hodgkin's Lymphoma in Children and Adolescents Active, not recruiting NCT01088750 Phase 4 cyclophosphamide;prednisolone;vinblastine sulfate
2 A Non-Randomized Phase III Study of Response Adapted Therapy for the Treatment of Children With Newly Diagnosed High Risk Hodgkin Lymphoma Unknown status NCT01026220 Phase 3 doxorubicin hydrochloride;liposomal vincristine sulfate;vinorelbine tartrate;cyclophosphamide;etoposide phosphate;prednisone;ifosfamide
3 Ofatumumab in Relapsed Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) Completed NCT01187303 Phase 2 Ofatumumab
4 Ibrutinib in Relapsed Nodular Lymphocyte-predominant Hodgkin Lymphoma (NLPHL) Active, not recruiting NCT02626884 Phase 2 Ibrutinib
5 A Phase I-II Trial of Fenretinide (4-HPR) + Rituximab in Patients With B-cell Lymphoma Terminated NCT00288067 Phase 1, Phase 2 fenretinide;rituximab

Search NIH Clinical Center for Nodular Lymphocyte Predominant Hodgkin Lymphoma

Genetic Tests for Nodular Lymphocyte Predominant Hodgkin Lymphoma

Anatomical Context for Nodular Lymphocyte Predominant Hodgkin Lymphoma

MalaCards organs/tissues related to Nodular Lymphocyte Predominant Hodgkin Lymphoma:

40
Bone Marrow, T Cells, Bone, Liver, Breast, Myeloid, Lymph Node

Publications for Nodular Lymphocyte Predominant Hodgkin Lymphoma

Articles related to Nodular Lymphocyte Predominant Hodgkin Lymphoma:

(show top 50) (show all 382)
# Title Authors PMID Year
1
Nodular lymphocyte-predominant Hodgkin lymphoma characteristics, management of primary and relapsed/refractory disease and outcome analysis: the first comprehensive report from the Middle East. 61
33794818 2021
2
Surgical Resection of Nodular Lymphocyte-Predominant Hodgkin Lymphoma of the Parotid Gland. 61
33270241 2021
3
Nodular lymphocyte predominant Hodgkin lymphoma: Experience of Polish Pediatric Leukemia/Lymphoma Study Group. 61
33734010 2021
4
Molecular biology of Hodgkin lymphoma. 61
33686198 2021
5
Nodular lymphocyte-predominant Hodgkin lymphoma involving the hard palate. 61
33503276 2021
6
PET-2-guided escalated BEACOPP for advanced nodular lymphocyte-predominant Hodgkin lymphoma: a subgroup analysis of the randomized German Hodgkin Study Group HD18 study. 61
33667668 2021
7
Additional characterization of LEF1 expression in nodular lymphocyte predominant Hodgkin lymphoma and classic Hodgkin lymphoma. 61
33743303 2021
8
Metachronous and clonally related classic Hodgkin lymphoma and nodular lymphocyte predominant Hodgkin lymphoma. 61
32951907 2021
9
Risk of hematological malignancies in the families of patients treated for nodular lymphocyte-predominant Hodgkin lymphoma. 61
33563316 2021
10
Genomic Landscape of Hodgkin Lymphoma. 61
33567641 2021
11
Outcome of relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: a North American analysis. 61
33517581 2021
12
The stage-specific roles of radiotherapy and chemotherapy in nodular lymphocyte predominant Hodgkin lymphoma patients: a propensity score-matched analysis of the SEER database. 61
33249743 2021
13
Lymphocyte predominant Hodgkin lymphoma, antigen-driven after all? 61
33044742 2021
14
How we treat mature B-cell neoplasms (indolent B-cell lymphomas). 61
33407745 2021
15
Minimising chemotherapy while optimising immune therapy for paediatric nodular lymphocyte-predominant Hodgkin's lymphoma. 61
33318747 2020
16
Nodular lymphocyte predominant Hodgkin lymphoma: executive summary of the American radium society appropriate use criteria. 61
33274673 2020
17
Lymphocyte predominant cells of nodular lymphocyte predominant Hodgkin lymphoma interact with rosetting T cells in an immunological synapse. 61
32815561 2020
18
Long-term follow-up of patients with nodular lymphocyte predominant Hodgkin lymphoma: A report from the Spanish Lymphoma Oncology Group. 61
33528063 2020
19
How I treat nodular lymphocyte-predominant Hodgkin lymphoma. 61
32877522 2020
20
[Nodular Lymphocyte-Predominant Hodgkin Lymphoma(NLPHL)Which Originate from the Mesentery-A Series of Two Cases]. 61
33468858 2020
21
Lymphoid enhancer binding factor 1 (LEF1) expression is significantly higher in Hodgkin lymphoma associated with Richter syndrome relative to de novo classic Hodgkin lymphoma. 61
32977233 2020
22
Anti-Ma-associated paraneoplastic cerebellar degeneration in a patient with nodular lymphocyte-predominant Hodgkin lymphoma: a case report. 61
32967629 2020
23
CD20-Negative Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A 20-Year Consecutive Case Series From a Tertiary Cancer Center. 61
32991677 2020
24
Role of FNA with core biopsy or cell block in patients with nodular lymphocyte-predominant Hodgkin lymphoma. 61
32343479 2020
25
Genomic characterization of diffuse large B-cell lymphoma transformation of nodular lymphocyte-predominant Hodgkin lymphoma. 61
32054999 2020
26
High-grade transformation in nodular lymphocyte predominant Hodgkin lymphoma. 61
32769356 2020
27
A case of nodular lymphocyte predominant Hodgkin lymphoma with unexpected EBV-latency type. 61
32683458 2020
28
Primary Extranodal Nodular Lymphocyte Predominant Hodgkin Lymphoma Involving the Thyroid. 61
31292857 2020
29
Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG. 61
32211877 2020
30
Diagnostic utility of STAT6YE361 expression in classical Hodgkin lymphoma and related entities. 61
31822802 2020
31
Lymphocyte predominant cells detect Moraxella catarrhalis-derived antigens in nodular lymphocyte-predominant Hodgkin lymphoma. 61
32424289 2020
32
Epidemiology of classic and nodular lymphocyte predominant hodgkin lymphoma in Finland in 1996-2015. 61
31910680 2020
33
Bone marrow involvement by nodular lymphocyte-predominant Hodgkin lymphoma. 61
32124440 2020
34
Involved-Site Radiation Therapy for Early-Stage NLPHL. 61
32277917 2020
35
A rare face of follicular lymphoma: reverse variant of follicular lymphoma. 61
32245492 2020
36
Primary therapy and survival among patients with nodular lymphocyte-predominant Hodgkin lymphoma: a population-based analysis in the Netherlands, 1993-2016. 61
31682006 2020
37
Long-Term Follow-Up of Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma Treated in the HD7 to HD15 Trials: A Report From the German Hodgkin Study Group. 61
31626571 2020
38
Rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: long-term follow-up of a phase 2 study from the German Hodgkin Study Group. 61
31636342 2020
39
"Popcorn cells" in intraoperative touch imprints of nodular lymphocyte-predominant Hodgkin lymphoma. 61
31793243 2020
40
The life and death of the germinal center. 61
31751845 2020
41
Role of Specific B-Cell Receptor Antigens in Lymphomagenesis. 61
33363034 2020
42
Nodular lymphocyte predominant Hodgkin lymphoma: pathology, clinical course and relation to T-cell/histiocyte rich large B-cell lymphoma. 61
31785822 2020
43
Meningeal Relapse of Nodular Lymphocyte Predominant Hodgkin Lymphoma Transformed to T-Cell/Histiocyte-Rich Large B-Cell Lymphoma: A Case Report. 61
33042818 2020
44
CD30 Cross-Reactivity and Expression in Feline Normal Tissues and Lymphomas. 61
31640480 2020
45
Immunophenotypic Characterization and Purification of Neoplastic Cells from Lymph Nodes Involved by T-Cell/Histiocyte-rich Large B-cell Lymphoma by Flow Cytometry and Flow Cytometric Cell Sorting. 61
31254446 2020
46
Clinical features and survival of patients with T-cell/histiocyte-rich large B-cell lymphoma: analysis of the National Cancer Data Base. 61
31287335 2019
47
The time to relapse correlates with the histopathological growth pattern in nodular lymphocyte predominant Hodgkin lymphoma. 61
31396979 2019
48
The complementary role of insulin-like growth factor II mRNA-binding protein 3 (IMP3) in diagnosis of Hodgkin's lymphoma. 61
31319330 2019
49
Frontline management of nodular lymphocyte predominant Hodgkin lymphoma - a retrospective UK multicentre study. 61
31344253 2019
50
IgG4-related lymphadenopathy masquerading as Hodgkin lymphoma: lessons from a pathologist's desk. 61
31511261 2019

Variations for Nodular Lymphocyte Predominant Hodgkin Lymphoma

Expression for Nodular Lymphocyte Predominant Hodgkin Lymphoma

Search GEO for disease gene expression data for Nodular Lymphocyte Predominant Hodgkin Lymphoma.

Pathways for Nodular Lymphocyte Predominant Hodgkin Lymphoma

Pathways related to Nodular Lymphocyte Predominant Hodgkin Lymphoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.54 CCND1 BCL6
2 11.43 CCND1 BCL6
3 11.38 CCND1 BCL6
4 11.08 PDCD1 BCL6
5
Show member pathways
10.96 CFLAR CCND1
6 10.74 CFLAR CCND1
7 10.33 CFLAR CCND1

GO Terms for Nodular Lymphocyte Predominant Hodgkin Lymphoma

Biological processes related to Nodular Lymphocyte Predominant Hodgkin Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of NF-kappaB transcription factor activity GO:0051092 8.96 CFLAR CARD16
2 cellular response to hypoxia GO:0071456 8.62 CFLAR CARD16

Sources for Nodular Lymphocyte Predominant Hodgkin Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....